Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Reporting Date: June 3, 2024
Event: Results of the 2024 Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not contain financial performance data. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not reported in this document.
Material Changes
No material financial changes are reported. The filing details the outcome of shareholder votes regarding corporate governance and executive compensation.
Outlook, Management Commentary, and Risks
Shareholder Voting Results:
- Proposal 1 (Election of Directors): Stockholders elected Blake Borgeson, Ph.D., and Dean Y. Li, M.D., Ph.D., as Class III directors to serve until the 2027 annual meeting.
- Blake Borgeson: 165,914,956 votes For; 26,093,759 votes Withheld.
- Dean Y. Li: 166,211,058 votes For; 25,797,657 votes Withheld.
- Proposal 2 (Executive Compensation): The advisory resolution to approve executive compensation was approved.
- Votes For: 188,317,831
- Votes Against: 2,887,180
- Abstain: 803,704
Management Commentary/Risks: The filing text does not provide specific management commentary, forward-looking guidance, or risk factors beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the definitive Proxy Statement filed on April 23, 2024, for detailed descriptions of the director nominees and executive compensation packages.
- Confirm the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Note that the directors elected will serve until the 2027 annual meeting.